News

Vertex Pharmaceuticals has agreed to acquire Crinetics Pharmaceuticals in an all-cash transaction valued at approximately $10 billion, expanding Vertex’s presence in rare endocrine…
Read More...

Arcturus Therapeutics has entered into a strategic collaboration with Thermo Fisher Scientific to support the late-stage development and potential commercialization of ARCT-032, an…
Read More...

Lonza has acquired rights to Nona Biosciences’ transferrin receptor 1, or TfR1, blood-brain barrier technology, expanding its capabilities in central nervous system drug development and…
Read More...

Ipsen has agreed to acquire Memo Therapeutics AG in a deal designed to strengthen its rare disease pipeline with potravitug, a Phase II clinical-stage monoclonal antibody for BK…
Read More...

AlzeCure Pharma AB has signed an out-licensing and collaboration agreement with Danish biotech company QuantumCell ApS for the global rights to its NeuroRestore platform, including its…
Read More...

Inocras Inc. and AimedBio have entered into a strategic partnership focused on using whole genome sequencing and multi-omics data to accelerate the development of antibody-drug…
Read More...

Insilico Medicine has entered into a strategic collaboration with Takeda Pharmaceutical Company to accelerate AI-driven drug discovery, leveraging its proprietary Pharma.AI platform to…
Read More...

Novartis has received European Commission approval for Itvisma® (onasemnogene abeparvovec), expanding access to gene replacement therapy for children, teenagers and adults living with…
Read More...

Sanofi has reported positive Phase 3 results for Nexviazyme, also known as avalglucosidase alfa, in infants with infantile-onset Pompe disease, a rare and life-threatening genetic…
Read More...

Vertex Pharmaceuticals has received expanded approval from the U.S. Food and Drug Administration for CASGEVY® (exagamglogene autotemcel), allowing the gene-editing therapy to be used in…
Read More...

Innovent Biologics and Eli Lilly and Company have entered into a new distribution and promotion agreement for Verzenios® (abemaciclib) in mainland China, expanding their commercial…
Read More...

Zymeworks Inc. has agreed to acquire Theravance Biopharma, Inc. in an all-cash transaction valued at approximately $929 million, marking a significant consolidation in the biotechnology…
Read More...

Eli Lilly and Company has moved a step closer to expanding the use of its blood cancer therapy Jaypirca (pirtobrutinib) in Europe after receiving a positive opinion from the European…
Read More...

Talawar Tx Inc., a biotechnology company developing next-generation bispecific antibody therapies for immunology and inflammatory diseases, has signed a definitive business combination…
Read More...

AstraZeneca and YMCA of the USA (Y-USA) have launched a five-year, multimillion-dollar partnership aimed at improving cancer awareness, increasing screening and early detection rates,…
Read More...

Antares Therapeutics has entered into a strategic collaboration with Novartis to discover, develop, and commercialize a new generation of small-molecule cancer therapies targeting…
Read More...

Ionis Pharmaceuticals has received U.S. Food and Drug Administration (FDA) approval for TRYNGOLZA (olezarsen), a first-of-its-kind therapy designed to reduce triglyceride levels and…
Read More...

RQ Bio has secured $115 million (£85.5 million) in an oversubscribed Series A financing, providing the biotechnology company with significant resources to advance the clinical…
Read More...

Merck has secured European Union approval for a new perioperative treatment regimen combining KEYTRUDA (pembrolizumab) and Padcev (enfortumab vedotin-ejfv) for adults with resectable…
Read More...

Merck KGaA, Darmstadt, Germany, has announced a definitive agreement to acquire U.S.-based life sciences company Bio-Techne Corporation in an all-cash transaction valued at…
Read More...